Can Ozempic, Wegovy, Mounjaro, and other GLP-1 medications cause vision loss? Emerging research has found a possible association between these medications and NAION, a rare optic nerve condition that can cause sudden, painless, and potentially permanent vision loss.
Dr. Joseph Allen is joined by Dr. Andrew Morgenstern, an optometrist, clinical educator, and leading authority on GLP-1 medications and eye health. They examine what current evidence shows, how significant the risk may be, and which patients may require closer monitoring.
Dr. Morgenstern explains how NAION affects blood flow to the optic nerve, what a “disc at risk” means, and why people with diabetes, high blood pressure, high cholesterol, cardiovascular disease, or existing retinal conditions may be more vulnerable.
GLP-1 medications can provide significant benefits for diabetes, weight management, and overall health. This episode is not intended to tell anyone to stop taking a prescribed medication. Instead, it provides information to help patients recognize urgent warning signs and discuss their individual risks with their prescribing doctor and eye care team.
What You’ll Learn
✅ Whether Ozempic and other GLP-1 medications may increase vision-loss risk
✅ The symptoms of NAION and when sudden vision changes require emergency care
✅ Who may be more vulnerable to GLP-1-related eye complications
✅ Why baseline and annual comprehensive dilated eye exams are important
🔔 Subscribe for more trusted eye health education: https://www.youtube.com/@DoctorEyeHealth
Timestamps
- 00:00 Can Ozempic cause blindness?
- 02:12 Is vision risk limited to semaglutide?
- 04:30 Understanding NAION and optic nerve strokes
- 09:35 Warning signs of NAION
- 11:41 Should you call an eye doctor or visit the emergency room?
- 15:45 Can vision recover after NAION?
- 18:21 Low-vision rehabilitation and protecting the second eye
- 21:11 When GLP-1-related eye complications may occur
- 24:20 Blood sugar, A1C, and gradual dose increases
- 28:19 What current research says about absolute risk
- 31:35 Who may be at greater risk?
- 34:32 What is a “disc at risk”?
- 38:37 Diabetic retinopathy and macular degeneration
- 41:47 Why annual dilated eye exams matter
- 45:24 Benefits of GLP-1 medications
- 48:51 Understanding single, double, and triple agonist drugs
- 51:33 Final eye-health and prevention recommendations
Key Takeaways
🔹 NAION typically causes sudden, painless vision loss in one eye. Symptoms may include missing areas of vision, dim or blurry sight, and reduced color perception.
🔹 The reported risk remains low, but certain studies suggest GLP-1 use may increase the risk of NAION. Individual risk depends on eye anatomy, medical history, and cardiovascular health.
🔹 People over 50 and those with diabetes, high blood pressure, high cholesterol, cardiovascular disease, glaucoma, macular degeneration, or existing diabetic retinopathy may require closer monitoring.
🔹 Do not stop or change a prescribed GLP-1 medication without speaking with your healthcare professional. Seek urgent medical attention for sudden vision loss or a new missing area in your visual field.
These are the strongest related Doctor Eye Health videos to include. I would place the GLP-1 video first because it is the closest match to this interview.
✅ Watch Next:
GLP-1 Blindness Risk: Should You Be Worried?
https://www.youtube.com/watch?v=W9JWFhRKae0
This Is What Sugar Does to Your Eyes
https://www.youtube.com/watch?v=71YkAYB31ZI
5 Signs and Symptoms of Diabetic Eye Disease
https://www.youtube.com/watch?v=8vI_ptfl-eQ
Why You Need an Eye Exam
https://www.youtube.com/watch?v=LQm6iSOeLvo
About Dr. Andrew Morgenstern
Dr. Andrew Morgenstern is an optometrist and clinical educator who has served as a subject-matter expert with the United States Defense Health Agency’s Vision Center of Excellence. He is also a clinician at Walter Reed, an assistant professor of surgery at the Uniformed Services University, and director of the American Optometric Association’s Evidence-Based Optometry Committee.
Website: https://andrewmorgenstern.com/
LinkedIn: https://www.linkedin.com/in/andrewmorgenstern/
Resources and Research Mentioned
American Optometric Association GLP-1 Clinical Report:
https://www.aoa.org/AOA/Documents/Practice%20Management/Clinical%20Guidelines/AOA%20GLP-1_EBO_clinical-report.pdf
Semaglutide and the Risk of NAION:
https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2820255
GLP-1 Medications and Macular Degeneration:
https://jamanetwork.com/journals/jamaophthalmology/article-abstract/2834964
Semaglutide and Diabetic Retinopathy:
https://www.nejm.org/doi/10.1056/NEJMoa1607141
Connect With Doctor Eye Health
Website: Doctor Eye Health https://www.doctoreyehealth.com/
YouTube: Doctor Eye Health https://www.youtube.com/@DoctorEyeHealth
Instagram: @doctoreyehealth https://www.instagram.com/doctoreyehealth
TikTok: Doctor Eye Health https://www.tiktok.com/@doctoreyehealth
Facebook: Doctor Eye Health https://www.facebook.com/DoctorEyeHealth
LinkedIn: Dr. Joseph Allen https://www.linkedin.com/
⚠️ DISCLAIMER: This episode is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Contact an eye doctor or healthcare professional if you experience persistent redness, yellowing of the eyes, a sudden change in pupil size, eye pain, vision loss, double vision, or another unexplained eye change.
